Darzalex Regimen May Improve MRD Responses in Multiple Myeloma
In patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, adding Darzalex (daratumumab) to Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone (VRd) demonstrated improved minimal-residual disease (MRD) responses. …